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Purpose: Previous reports have identified noninfectious uveitis as a potential sequela   following 
both intravitreal bevacizumab and ranibizumab injections. We present two unique cases of 
acute anterior uveitis following intravitreal bevacizumab that did not occur with subsequent 
ranibizumab injections.
Methods: Case report.
Conclusion: These cases may reflect differences in the etiology of anterior uveitis   following 
intravitreal bevacizumab and ranibizumab. Given these differences, it may be reasonable 
to offer ranibizumab to patients who have experienced presumed bevacizumab-induced 
anterior uveitis.
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Introduction
Studies monitoring the safety of intravitreal bevacizumab and ranibizumab injec-
tions have identified noninfectious acute anterior uveitis as a sequela of both drugs.1,2 
Although a large retrospective case series failed to detect a significant difference in 
the incidence of anterior uveitis after either bevacizumab or ranibizumab,3 randomized 
prospective trials evaluating this complication are lacking.4 We present two cases of 
acute anterior uveitis following intravitreal bevacizumab that did not recur with sub-
sequent ranibizumab therapy. Uniquely, the first case describes the risk of continued 
intravitreal bevacizumab following presumed bevacizumab-related acute anterior 
uveitis, and the second presents a case of unilateral acute anterior uveitis in a patient 
who had received long-term bilateral intravitreal bevacizumab injections.
Case 1
A 75-year-old woman with a history of hypothyroidism received two doses of 
  bevacizumab 8 weeks apart for exudative age-related macular degeneration (AMD) 
in the right eye. Five days after the second injection, the patient reported tearing, light 
sensitivity, and decreased vision. The Snellen visual acuity decreased from 20/50 to 
finger counting. Slit lamp biomicroscopy revealed 1+ conjunctival vascular injection, 
1+ corneal edema with intact epithelium, and 1+ flare. Anterior chamber cellular 
reaction, hypopyon, or vitritis were not documented. A diagnosis of ‘decompensated 
corneal dystrophy’ was made and sodium chloride hypertonicity ophthalmic ointment 
5% (Muro-128®, Bausch and Lomb, Rochester, NY) and prednisolone acetate 1% Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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were initiated. The visual acuity and ocular findings report-
edly returned to baseline within 1 week.
On initial presentation at our center 4 months later, the 
best corrected visual acuity was 20/30. Slit lamp biomicros-
copy revealed anterior basement membrane dystrophy but no 
other corneal pathology or intraocular inflammation. Dilated 
fundoscopic examination revealed asteroid hyalosis and a 
serous pigment epithelial detachment without subretinal fluid 
or hemorrhage. Observation was recommended.
Two months later, the visual acuity dropped to 20/70, 
and the pigment epithelial detachment increased in height 
on optical coherence tomography (OCT). The patient 
underwent a series of 3-monthly intravitreal ranibizumab 
(0.5 mg/0.05 mL) injections without incident, consistent with 
reports in the literature supporting the use of anti-vascular 
endothelial growth factor (VEGF) therapy to treat AMD-
associated serous pigment epithelial detachments.5,6 The 
visual acuity subsequently improved to 20/40 with marked 
resolution of the pigment epithelial detachment on OCT.
Due to patient preference and the diagnostic ambiguity of 
the original event, maintenance therapy was initiated with a 
retrial of bevacizumab. Twelve days later, the patient noted 
tearing, light sensitivity, and pain in the eye. The visual acuity 
dropped to 20/100. Slit lamp biomicroscopy revealed 2+ con-
junctival vascular injection, corneal edema, and 2+ cell and 
flare. Dilated fundoscopy was stable. The patient was treated 
with topical prednisolone acetate 1% and homatropine 5% for 
acute anterior uveitis, and the symptoms resolved completely 
within 4 weeks. The patient continues to receive monthly 
ranibizumab injections without relapse of anterior uveitis.
Case 2
A 69-year-old man with a history of diabetes mellitus and pri-
mary open-angle glaucoma received a diagnosis of bilateral 
exudative AMD after reporting a 6-week history of decreased 
vision. He was initially treated with monthly ranibizumab 
injections (two in each eye) before switching to   bevacizumab. 
He continued to receive intravitreal bevacizumab injec-
tions in each eye every 8 weeks for the next 2 years with-
out   complication. Four days after a routine bevacizumab 
injection in the left eye, he noticed increasing redness and 
foreign body sensation. The visual acuity dropped from 
20/25 to 20/40 and slit lamp examination revealed keratic 
precipitates with trace cell in the anterior chamber. There 
was no involvement of the left vitreous cavity or right eye. 
The eye was treated with topical prednisolone acetate 1% for 
acute anterior uveitis. After 4 weeks, the anterior chamber 
cell and keratic precipitates had resolved. He subsequently 
received intravitreal ranibizumab injections in each eye every 
6 weeks, and tolerated the therapy well with no evidence of 
recurrent uveitis.
Discussion
The anti-VEGF agents, bevacizumab and ranibizumab, have 
enhanced the management of exudative AMD.2 However, the 
safety profile of these drugs continues to undergo   scrutiny, 
and noninfectious intraocular inflammation is a known 
adverse effect of both drugs.1 A retrospective case series 
of nearly 2000 injections reported no significant difference 
between the incidence of post-injection anterior uveitis 
(1.57% bevacizumab vs 1.38% ranibizumab; P . 0.80) or 
panuveitis (0.39% vs 0.41%; P = 1.0).3 However, random-
ized prospective trials comparing the rates of uveitis between 
ranibizumab and bevacizumab are lacking, leading some 
authors to question whether the complication rates are truly 
similar.4,7 Although underpowered to compare this relatively 
rare outcome, the 1-year clinical trial results from the 
  Comparison of Age-Related Macular Degeneration Treatment 
Trials reported anterior uveitis in ,1% of study eyes receiv-
ing either treatment.8
In retrospect, we believe that the first case was bevacizum-
ab-related anterior uveitis that was originally misdiagnosed. 
AMD treatment later resumed uneventfully with ranibizumab 
and was then switched to bevacizumab for maintenance 
therapy. The anterior uveitis promptly relapsed. To our 
knowledge, this is the first report in the literature to describe 
recurrent bevacizumab-related anterior uveitis following a 
retrial of intravitreal bevacizumab.
The second patient likely experienced bevacizumab-
related anterior uveitis after previously tolerating the medi-
cation without difficulty, which has been reported.9 His case 
is unique in that he was receiving bilateral bevacizumab 
injections, yet developed only unilateral anterior uveitis. Both 
cases corroborate reports from Raja et al10 and   Georgopoulos 
et al14 describing the safe administration of intravitreal ranibi-
zumab after bevacizumab-related uveitis.
The etiology of this drug-induced uveitis is speculative 
at best, since it occurs rarely and there is no histopathologic 
data with which to correlate the phenomenon. The follow-
ing mechanisms have been proposed: (1) toxic response to 
the drug or excipients; (2) direct blood-aqueous or blood-
retinal barrier compromise by drug or excipients; (3) immune 
response to the drug or excipients; and (4) rebound inflam-
mation secondary to VEGF suppression.11Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The excipients of both preparations are nearly   identical: 
trehalose dihydrate, sodium phosphate, polysorbate 20, 
and sterile water (histidine hydrochloride – in ranibizumab 
only), which makes it more difficult to implicate them in 
a differential immune response. Moreover, there are no 
reported cases of hypersensitivity to any of these excipients 
in the literature.
Alternatively, this reaction may occur as an immunologic 
response to the Fc protein portion of the full-length antibody 
molecule itself; ranibizumab is an Fab fragment whereas 
bevacizumab is a full-length antibody (Fab and Fc) derived 
from the same parent molecule. This is an attractive explana-
tion since other drugs, such as heparin, provoke a differential 
immune response based on antigenic load. Unfractionated 
heparin has a higher propensity to cause heparin-induced-
thrombocytopenia than low-molecular weight heparin, pre-
sumably due to the larger size of the full heparin molecule 
and its enhanced ability to form immunogenic complexes 
with other platelet factors.12
The exact immunologic mechanism underlying these 
cases of uveitis is difficult to ascertain without histopatho-
logic data, though a delayed-type hypersensitivity reaction 
seems possible given the several-day lapse in time between 
exposure to bevacizumab and the onset of uveitis symptoms. 
Interestingly, reports in the cancer literature show that infu-
sions of monoclonal antibodies such as bevacizumab cause 
immediate hypersensitivity reactions in the majority of 
cases, though delayed-type reactions can be seen in up to 
30% of patients.13
Aside from the obvious difference in molecular size 
between ranibizumab and bevacizumab, it is also possible that 
differences in drug production could explain the variation in 
immunogenicity.14 Bevacizumab is harvested as a glycosy-
lated product of human ovarian cancer cells, whereas ranibi-
zumab is a non-glycosylated product of bacterial metabolism. 
The glycosylation of bevacizumab creates more potential 
immunogenic sites compared to the non-glycosylated ranibi-
zumab, which could translate into a higher propensity for 
bevacizumab to cause inflammatory reactions.
Furthermore, it is interesting to speculate on how the vari-
able dosing regimens for bevacizumab and ranibizumab may 
contribute to the development of inflammatory   complications. 
The predominant anti-VEGF dosing schedules used for 
AMD treatment include fixed monthly injections, ‘treat and 
extend’, and as-needed (pro re nata [PRN]) injections based 
on symptoms and OCT findings. We could not find anything 
in the literature to suggest that one dosing regimen may result 
in more complications than another, though it would seem 
reasonable to postulate that more frequent exposure to a drug 
could result in a higher likelihood of it causing inflamma-
tory/immunogenic complications. Data from the second year 
of the Comparison of Age-Related Macular Degeneration 
Treatment Trial may help to more fully elucidate the role that 
anti-VEGF dosing schedules play in predisposing patients to 
inflammatory ocular complications.
Despite our conjecture regarding the enhanced immu-
nogenic potential of bevacizumab over ranibizumab, a 
large retrospective study failed to detect a significant 
difference in the rates of uveitis between the two drugs.3 
Nevertheless, bevacizumab has not been subjected to nearly 
the same scrutiny (in the form of rigorous clinical trials) 
as ranibizumab, and thus safety data for bevacizumab 
is relatively lacking.4 The results of future prospective 
randomized trials comparing the efficacy and side-effect 
profile of ranibizumab to bevacizumab might help to 
more definitively answer the questions surrounding the 
inflammatory sequelae of intravitreal ranibizumab and 
bevacizumab injections.
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